Muraglitazar

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameMuraglitazar
Drug Alias Name莫格列扎莫格列他PargluvaBMS-298585
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonistsPeroxisome proliferator-activated receptor α agonists
TargetsPeroxisome proliferator-activated receptor γPeroxisome proliferator-activated receptor α
Therapy Area/IndicationsDyslipidemiasDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[29] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol Myers Squibb SrlcompanyMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsDyslipidemiasDiabetes Mellitus, Type 2Diabetes Mellitus

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG